Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Dyspepsia future or investigational therapies
Introduction
Future or Investigational Therapies
Future or Investigational Therapies
A 2004 meta-analysis pooling data from three double-blind placebo-controlled studies found the multiple herbal extract Iberogast to be significantly more effective than placebo (p value = 0.001) at treating patients with functional dyspepsia through the targeting of multiple dyspeptic pathologies.[1] This German-made phytopharmaceutical was found to be equivalent to cisapride and significantly superior to metochlopramide at reducing the symptoms of functional dyspepsia over a four week period.[2][3] Retrospective surveillance of 40,961 children (12 years and under) found no serious side-effects.[4]
References
References
- ↑ Melzer J, Rosch W, Reichling J, Brignoli R, Saller R (2004). “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW-5 (Iberogast)”. Aliment Pharmacol Ther. 20: 1279&ndash, 87.
- ↑ Rosch w, Vinson B, Sassin, I (2002). “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia”. Z Gastroenterol. 40: 401&ndash, 8.
- ↑ Hanisch J, Bock P, Vinson B (2005). “The efficacy and safety of STW 5 versus Metochlopramide oral for functional dyspepsia under practice conditions (in German)”. Med Klinik. 100. Text “pages107” ignored (help)
- ↑ Liechtle K (1999). “Experience reports on the use of Iberogast in children (in German)”. Forschungsbericht Steigerwald Arzneimittelwerk. GmbH.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]